Published in J Neurosci on June 03, 2009
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98
Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br J Pharmacol (2012) 1.69
CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci (2010) 1.38
Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci U S A (2009) 1.26
Htr2a Gene and 5-HT(2A) Receptor Expression in the Cerebral Cortex Studied Using Genetically Modified Mice. Front Neurosci (2010) 1.23
Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo. J Neurosci (2010) 1.21
A Gαs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons. Neuropsychopharmacology (2012) 1.17
Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Test Anal (2012) 1.13
Chemogenetic inactivation of ventral hippocampal glutamatergic neurons disrupts consolidation of contextual fear memory. Neuropsychopharmacology (2014) 1.10
The presynaptic component of the serotonergic system is required for clozapine's efficacy. Neuropsychopharmacology (2010) 1.09
Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. Neuropharmacology (2013) 1.05
Assessing serotonin receptor mRNA editing frequency by a novel ultra high-throughput sequencing method. Nucleic Acids Res (2010) 1.00
Serotonin 5-HT2C receptor protein expression is enriched in synaptosomal and post-synaptic compartments of rat cortex. J Neurochem (2010) 0.98
Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology (Berl) (2012) 0.97
Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation. Neuropharmacology (2011) 0.97
Quantitative analysis of glutamatergic innervation of the mouse dorsal raphe nucleus using array tomography. J Comp Neurol (2011) 0.95
Review: disruption of the postsynaptic density in Alzheimer's disease and other neurodegenerative dementias. Am J Alzheimers Dis Other Demen (2010) 0.95
HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia. ChemMedChem (2010) 0.94
A novel role for PSD-95 in mediating ethanol intoxication, drinking and place preference. Addict Biol (2011) 0.93
Glycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin Neurotransmission. Front Mol Neurosci (2011) 0.90
Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. Psychopharmacology (Berl) (2013) 0.88
Motor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95. J Neurogenet (2014) 0.87
Serotonin receptor signaling and regulation via β-arrestins. Crit Rev Biochem Mol Biol (2010) 0.86
Modulation of behavior by scaffolding proteins of the post-synaptic density. Neurobiol Learn Mem (2013) 0.86
Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model. Neuropharmacology (2013) 0.86
Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther (2011) 0.85
Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex. Neuroscience (2015) 0.84
Disrupting 5-HT(2A) receptor/PDZ protein interactions reduces hyperalgesia and enhances SSRI efficacy in neuropathic pain. Mol Ther (2010) 0.84
The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol (2015) 0.84
Progressive maturation of silent synapses governs the duration of a critical period. Proc Natl Acad Sci U S A (2015) 0.83
Functional status of the serotonin 5-HT2C receptor (5-HT2CR) drives interlocked phenotypes that precipitate relapse-like behaviors in cocaine dependence. Neuropsychopharmacology (2013) 0.83
In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. PLoS One (2016) 0.82
Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo. Transl Psychiatry (2011) 0.82
The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol (2014) 0.82
p90 Ribosomal S6 kinase 2, a novel GPCR kinase, is required for growth factor-mediated attenuation of GPCR signaling. Biochemistry (2010) 0.81
Peptide inhibitors disrupt the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog to allosterically modulate cellular signaling and behavior. J Neurosci (2013) 0.81
Repressive epigenetic changes at the mGlu2 promoter in frontal cortex of 5-HT2A knockout mice. Mol Pharmacol (2013) 0.80
Neuronal ablation of p-Akt at Ser473 leads to altered 5-HT1A/2A receptor function. Neurochem Int (2013) 0.78
5-hydroxytryptamine 2C receptors tonically augment synaptic currents in the nucleus tractus solitarii. J Neurophysiol (2012) 0.78
Individual Differences in Impulsive Action Reflect Variation in the Cortical Serotonin 5-HT2A Receptor System. Neuropsychopharmacology (2015) 0.77
Striatal serotonin 2C receptors decrease nigrostriatal dopamine release by increasing GABA-A receptor tone in the substantia nigra. J Neurochem (2014) 0.75
Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions. Int J Mol Sci (2017) 0.75
A genomic lifespan program that reorganises the young adult brain is targeted in schizophrenia. Elife (2017) 0.75
Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science (2002) 17.71
Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature (1997) 7.92
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature (1998) 6.29
Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms. Nature (2001) 5.98
NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res (2000) 4.66
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) (2001) 4.52
Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature (1995) 4.36
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A (2002) 4.34
Consciousness and complexity. Science (1998) 4.31
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov (2004) 4.31
Hallucinogens. Pharmacol Ther (2004) 4.01
The expanded biology of serotonin. Annu Rev Med (2009) 3.87
The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology (1999) 3.78
Postsynaptic signaling and plasticity mechanisms. Science (2002) 3.46
Postsynaptic density 95 controls AMPA receptor incorporation during long-term potentiation and experience-driven synaptic plasticity. J Neurosci (2004) 3.30
Auxiliary subunits assist AMPA-type glutamate receptors. Science (2006) 3.10
Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron (2007) 2.98
NGL family PSD-95-interacting adhesion molecules regulate excitatory synapse formation. Nat Neurosci (2006) 2.91
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther (1989) 2.78
Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron (2004) 2.76
A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell (2008) 2.76
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry (2004) 2.60
Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry (2004) 2.25
Alternative N-terminal domains of PSD-95 and SAP97 govern activity-dependent regulation of synaptic AMPA receptor function. Neuron (2006) 2.25
Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther (2008) 2.17
Molecular dissociation of the role of PSD-95 in regulating synaptic strength and LTD. Neuron (2008) 2.15
RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem (1999) 2.10
MAP2 is localized to the dendrites of hippocampal neurons which develop in culture. Brain Res (1984) 1.77
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci (1984) 1.73
In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology (2004) 1.73
Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci (2003) 1.64
The pipeline and future of drug development in schizophrenia. Mol Psychiatry (2007) 1.63
Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry (2003) 1.62
5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A (1998) 1.61
Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A (2008) 1.51
Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology (2000) 1.43
Serotonin and hallucinogens. Neuropsychopharmacology (1999) 1.40
5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system. Proc Natl Acad Sci U S A (1989) 1.39
Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse (1997) 1.38
Synaptic multiprotein complexes associated with 5-HT(2C) receptors: a proteomic approach. EMBO J (2002) 1.35
A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. J Biol Chem (2003) 1.28
RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. Br J Pharmacol (2001) 1.27
Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) (1997) 1.25
The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets of PDZ proteins. J Biol Chem (2004) 1.25
Perturbed dentate gyrus function in serotonin 5-HT2C receptor mutant mice. Proc Natl Acad Sci U S A (1998) 1.21
Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol Ther (2004) 1.19
Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Res (2003) 1.18
Optimized protocols for the simultaneous preparation of primary neuronal cultures of the neocortex, hippocampus and cerebellum from individual newborn (P0.5) C57Bl/6J mice. J Neurosci Methods (2005) 1.08
Ligand binding of the second PDZ domain regulates clustering of PSD-95 with the Kv1.4 potassium channel. J Biol Chem (2001) 1.08
A-to-I pre-mRNA editing of the serotonin 2C receptor: comparisons among inbred mouse strains. Gene (2006) 1.06
The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro. Neuroscience (2003) 1.05
WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther (2006) 1.03
Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications. CNS Drug Rev (2007) 1.02
Enhanced activation of Akt and extracellular-regulated kinase pathways by simultaneous occupancy of Gq-coupled 5-HT2A receptors and Gs-coupled 5-HT7A receptors in PC12 cells. J Neurochem (2005) 1.02
Opposite effects of PSD-95 and MPP3 PDZ proteins on serotonin 5-hydroxytryptamine2C receptor desensitization and membrane stability. Mol Biol Cell (2006) 1.00
Serotonin 5- HT (2C) receptor knockout mice: autoradiographic analysis of multiple serotonin receptors. J Neurosci Res (2002) 1.00
A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology (2002) 1.00
M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology (1999) 0.98
5-HT(2A) receptors stimulate mitogen-activated protein kinase via H(2)O(2) generation in rat renal mesangial cells. Am J Physiol Renal Physiol (2000) 0.98
WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J Pharmacol Exp Ther (2005) 0.96
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther (2001) 0.95
Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants. Br J Pharmacol (1992) 0.95
Neural activity mapping with inducible transcription factors. Neuroreport (1997) 0.94
Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol (1983) 0.92
Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology (Berl) (2003) 0.90
Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats. Biol Psychiatry (1999) 0.88
Cortical region interactions and the functional role of apical dendrites. Behav Cogn Neurosci Rev (2002) 0.88
Activation of extracellular-regulated kinase by 5-hydroxytryptamine(2A) receptors in PC12 cells is protein kinase C-independent and requires calmodulin and tyrosine kinases. J Pharmacol Exp Ther (2002) 0.87
RNA editing of the human serotonin 5-HT(2C) receptor delays agonist-stimulated calcium release. Mol Pharmacol (2000) 0.86
Histamine antagonizes serotonin and growth factor-induced mitogen-activated protein kinase activation in bovine tracheal smooth muscle cells. J Biol Chem (1995) 0.84
Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys. Neuroreport (2001) 0.84
The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. J Neural Transm (Vienna) (1999) 0.82
SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett (2005) 0.82
Transcriptional activation of c-Fos by constitutively active Galpha(16)QL through a STAT1-dependent pathway. Cell Signal (2006) 0.81
Apical dendrite activity in cognition and consciousness. Conscious Cogn (2005) 0.79
Comparative recovery kinetics of 5-hydroxytryptamine 1A, 1B, and 2A receptor subtypes in rat cortex after receptor inactivation: evidence for differences in receptor production and degradation. Mol Pharmacol (1994) 0.78
Influence of audiogenic seizures on synaptic facilitation in mouse hippocampal slices is mediated by N-methyl-D-aspartate receptor. Epilepsia (1994) 0.78
Modulation of B1 and B2 kinin receptors expression levels in the hippocampus of rats after audiogenic kindling and with limbic recruitment, a model of temporal lobe epilepsy. Int Immunopharmacol (2007) 0.77
The apical dendrite theory of consciousness. Neural Netw (2007) 0.77
The HUPO PSI's molecular interaction format--a community standard for the representation of protein interaction data. Nat Biotechnol (2004) 16.08
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci U S A (2007) 7.96
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
Relating protein pharmacology by ligand chemistry. Nat Biotechnol (2007) 6.61
An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell (2005) 5.60
Structure of the human κ-opioid receptor in complex with JDTic. Nature (2012) 5.18
Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. J Clin Invest (2011) 5.12
Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron (2009) 4.98
Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories. Neuron (2006) 4.80
Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron (2005) 4.78
Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci (2003) 4.50
Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci (2004) 4.44
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem (2003) 4.36
The expanded biology of serotonin. Annu Rev Med (2009) 3.87
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology (2003) 3.78
Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. J Neurochem (2006) 3.67
Characterization of the proteome, diseases and evolution of the human postsynaptic density. Nat Neurosci (2010) 3.67
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A (2004) 3.60
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol (2011) 3.60
Generation of a synthetic memory trace. Science (2012) 3.55
Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization. Nat Neurosci (2010) 3.55
The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science (2004) 3.54
Automated design of ligands to polypharmacological profiles. Nature (2012) 3.54
Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science (2003) 3.52
PDZ domain proteins: plug and play! Sci STKE (2003) 3.38
Food reward in the absence of taste receptor signaling. Neuron (2008) 3.37
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 3.35
Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron (2005) 3.30
Endocrine regulation of male fertility by the skeleton. Cell (2011) 3.20
Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature (2011) 3.19
Structure of the human smoothened receptor bound to an antitumour agent. Nature (2013) 3.08
Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature (2012) 2.96
Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron (2004) 2.76
A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell (2008) 2.76
Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol (2002) 2.76
Remote control of neuronal signaling. Pharmacol Rev (2011) 2.66
Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science (2004) 2.64
Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A (2003) 2.62
Structural features for functional selectivity at serotonin receptors. Science (2013) 2.60
Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol (2009) 2.60
Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol (2002) 2.54
A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci (2007) 2.54
Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev (2004) 2.49
The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem (2002) 2.47
SynGAP regulates ERK/MAPK signaling, synaptic plasticity, and learning in the complex with postsynaptic density 95 and NMDA receptor. J Neurosci (2002) 2.46
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
Engineering GPCR signaling pathways with RASSLs. Nat Methods (2008) 2.29
Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci U S A (2008) 2.23
The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci (2007) 2.22
Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. Neuron (2006) 2.19
Targeted tandem affinity purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins. Mol Syst Biol (2009) 2.17
Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol (2011) 2.10
Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron (2003) 2.03
Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci (2002) 2.01
Inhibition of mediodorsal thalamus disrupts thalamofrontal connectivity and cognition. Neuron (2013) 2.01
MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci U S A (2009) 2.00
Proteomic analysis of in vivo phosphorylated synaptic proteins. J Biol Chem (2004) 1.99
DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu Rev Pharmacol Toxicol (2014) 1.99
Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron (2006) 1.98
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98
The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron (2012) 1.97
Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther (2004) 1.97
Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci (2007) 1.93
Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov (2005) 1.93
Chemogenetic tools to interrogate brain functions. Annu Rev Neurosci (2014) 1.92
G-protein-coupled receptors at a glance. J Cell Sci (2003) 1.92
Evolutionary expansion and anatomical specialization of synapse proteome complexity. Nat Neurosci (2008) 1.91
A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A (2009) 1.90
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol (2013) 1.89
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease. Science (2009) 1.88
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther (2009) 1.88
Structural basis for molecular recognition at serotonin receptors. Science (2013) 1.86
Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol (2010) 1.86
Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A (2008) 1.85
Elimination of the vesicular acetylcholine transporter in the striatum reveals regulation of behaviour by cholinergic-glutamatergic co-transmission. PLoS Biol (2011) 1.84
N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology (2007) 1.83
Effect of torsinA on membrane proteins reveals a loss of function and a dominant-negative phenotype of the dystonia-associated DeltaE-torsinA mutant. Proc Natl Acad Sci U S A (2004) 1.78
Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist. J Med Chem (2005) 1.78
Dopaminergic control of sleep-wake states. J Neurosci (2006) 1.77
The role of neuronal complexes in human X-linked brain diseases. Am J Hum Genet (2007) 1.71
Phosphatidylinositol 3-kinase regulates the induction of long-term potentiation through extracellular signal-related kinase-independent mechanisms. J Neurosci (2003) 1.70
In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther (2003) 1.70
Synapse-associated protein 102/dlgh3 couples the NMDA receptor to specific plasticity pathways and learning strategies. J Neurosci (2007) 1.68
Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol Chem (2002) 1.67
Synaptic scaffold evolution generated components of vertebrate cognitive complexity. Nat Neurosci (2012) 1.67
The proteomes of neurotransmitter receptor complexes form modular networks with distributed functionality underlying plasticity and behaviour. Mol Syst Biol (2006) 1.66
Separable features of visual cortical plasticity revealed by N-methyl-D-aspartate receptor 2A signaling. Proc Natl Acad Sci U S A (2003) 1.66
A pharmacological organization of G protein-coupled receptors. Nat Methods (2013) 1.65
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA). Bioorg Med Chem Lett (2004) 1.65
Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol (2011) 1.61
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60
Mining the receptorome. J Biol Chem (2004) 1.58